

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128873 A1

(51) International Patent Classification:

A61P 25/16 (2006.01) C07D 487/04 (2006.01)
A61P 25/28 (2006.01) C07D 519/00 (2006.01)
A61P 37/00 (2006.01) C07D 473/00 (2006.01)
C07D 471/04 (2006.01) C07D 513/04 (2006.01)

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/059856

(22) International Filing Date:

12 December 2024 (12.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/609,320 12 December 2023 (12.12.2023) US
63/609,327 12 December 2023 (12.12.2023) US

(71) Applicant: **VIGIL NEUROSCIENCE, INC.** [US/US];
100 Forge Road, Suite 700, Watertown, Massachusetts
02472 (US).

(72) Inventors: **HOUZE, Jonathan B.**; c/o Vigil Neuroscience,
Inc., 100 Forge Road, Suite 700, Watertown, Massachusetts
02472 (US). **PANDYA, Bhaumik**; c/o Vigil Neuroscience,
Inc., 100 Forge Road, Suite 700, Watertown, Massachusetts
02472 (US).

(74) Agent: **ROSE GILLENTE, Marsha** et al.; STERNE,
KESSLER, GOLDSTEIN & FOX P.L.L.C., 1101 K Street
NW, 10th Floor, Washington, District of Columbia 20005
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE



(57) Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

WO 2025/128873 A1